Current Report Filing (8-k)
September 30 2021 - 4:31PM
Edgar (US Regulatory)
0001677077
false
0001677077
2021-09-30
2021-09-30
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
____________________________________________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
___________________________________________________________________
Date of Report (Date of earliest event reported): September
30, 2021
ALZAMEND NEURO,
INC.
(Exact name of registrant as specified in its charter)
Delaware
|
|
001-40483
|
|
81-1822909
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission File Number)
|
|
(I.R.S. Employer Identification No.)
|
3802 Spectrum Boulevard, Suite 112C, Tampa,
FL 33612
(Address of principal executive offices) (Zip Code)
(844) 722-6333
(Registrant's telephone number, including area
code)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, $0.0001 par value
|
|
ALZN
|
|
The Nasdaq Capital Market
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
|
Item 7.01
|
Regulation FD Disclosure.
|
On September 30, 2021, Alzamend Neuro, Inc. (the
“Company”) issued a press release to announce that the U.S. Food and Drug Administration has issued a written response
to the Company’s meeting request relating to its Type B Pre-Investigational New Drug application for the clinical development of
AL002. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.
The information contained in this Current Report
shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”)
or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The furnishing of the information
in this Current Report on Form 8-K is not intended to, and does not, constitute a representation that such furnishing is required by Regulation
FD or that the information contained in this Current Report on Form 8-K constitutes material investor information that is not otherwise
publicly available.
The Securities and Exchange Commission encourages
registrants to disclose forward-looking information so that investors can better understand the future prospects of a registrant and make
informed investment decisions. This Current Report on Form 8-K and exhibits may contain these types of statements, which are “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act of 1995, and which involve risks, uncertainties and
reflect the registrant’s judgment as of the date of this Current Report on Form 8-K. Forward-looking statements may relate to, among
other things, operating results and are indicated by words or phrases such as “expects,” “should,” “will,”
and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ
materially from those anticipated at the date of this Current Report on Form 8-K. Investors are cautioned not to rely unduly on forward-looking
statements when evaluating the information presented within.
|
Item 9.01
|
Exhibits and Financial Statements.
|
(d) Exhibits:
Exhibit
No.
|
|
Description
|
|
|
|
99.1
|
|
Press Release issued on September 30, 2021
|
101
|
|
Pursuant to Rule 406 of Regulation S-T, the cover page is formatted in Inline XBRL (Inline eXtensible Business Reporting Language).
|
104
|
|
Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101).
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ALZAMEND NEURO, INC.
|
|
|
|
|
Dated: September 30, 2021
|
/s/ Henry Nisser
|
|
Henry Nisser
|
|
Executive Vice President and General Counsel
|
Alzamend Neuro (NASDAQ:ALZN)
Historical Stock Chart
From Jul 2024 to Aug 2024
Alzamend Neuro (NASDAQ:ALZN)
Historical Stock Chart
From Aug 2023 to Aug 2024